Statement Of Cash Flows [Abstract]

ABIVAX - Filing #5984181

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for interest expense
14 203 EUR
24 827 EUR
7 028 EUR
Cash flows from (used in) operations before changes in working capital
155 495 EUR
118 395 EUR
51 933 EUR
Increase (decrease) in working capital
1 423 EUR
21 265 EUR
2 002 EUR
Adjustments for decrease (increase) in trade and other receivables
4 591 EUR
14 231 EUR
312,000 EUR
Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]
Adjustments for increase (decrease) in deferred income other than contract liabilities
1 763 EUR
81,000 EUR
26,000 EUR
Adjustments for increase (decrease) in employee benefit liabilities
74,000 EUR
109,000 EUR
143,000 EUR
Adjustments for impairment loss recognised in profit or loss, goodwill
EUR
EUR
13 632 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from sale or issue of treasury shares
434,000 EUR
10,000 EUR
143,000 EUR
Payments for share issue costs
446,000 EUR
28 111 EUR
3 280 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.